Effects of fluvastatin on prespecified cardiovascular end points
| End point | Unstable angina | Stable angina | ||||||
|---|---|---|---|---|---|---|---|---|
| Fluvastatin (n = 417) | Placebo (n = 407) | RR (95% CI) | p Value | Fluvastatin (n = 418) | Placebo (n = 416) | RR (95% CI) | p Value | |
| NA, not applicable. | ||||||||
| MACE without restenosis | 68 (16.3%) | 94 (23.1%) | 0.64 (0.46 to 0.88) | 0.006 | 66 (15.8%) | 92 (22.1%) | 0.69 (0.50 to 0.95) | 0.02 |
| Cardiac death/non-fatal MI | 22 (5.3%) | 35 (8.6%) | 0.60 (0.34 to 1.03) | 0.06 | 20 (4.8%) | 24 (5.8%) | 0.85 (0.46 to 1.55) | 0.59 |
| Time to first MACE | NA | NA | 0.72 (0.47 to 0.90) | 0.03 | NA | NA | 0.80 (0.60 to 1.07) | 0.13 |